866-997-4948(US-Canada Toll Free)

Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Dec 2017

Category :

Pharmaceutical

No. of Pages : 1575 Pages

Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2017, provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape.

Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells within the brain. Symptoms include headaches, blurred vision, nausea, vomiting, memory loss, speech difficulty, muscle weakness and loss of appetite. Risk factors include gender (male) and age. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glioblastoma Multiforme (GBM) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 11, 106, 65, 1, 8, 155, 23 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 12, 14, 1, 36 and 11 molecules, respectively.

Glioblastoma Multiforme (GBM) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Glioblastoma Multiforme (GBM) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Glioblastoma Multiforme (GBM) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 9
Glioblastoma Multiforme (GBM) - Overview 10
Glioblastoma Multiforme (GBM) - Therapeutics Development 11
Glioblastoma Multiforme (GBM) - Therapeutics Assessment 59
Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development 86
Glioblastoma Multiforme (GBM) - Drug Profiles 174
Glioblastoma Multiforme (GBM) - Dormant Projects 1503
Glioblastoma Multiforme (GBM) - Discontinued Products 1515
Glioblastoma Multiforme (GBM) - Product Development Milestones 1517
Appendix 1531

List of Tables
Number of Products under Development for Glioblastoma Multiforme (GBM), H2 2017 54
Number of Products under Development by Companies, H2 2017 56
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 57
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 58
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 59
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 60
Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 61
Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017 62
Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017 63
Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017 64
Number of Products under Development by Companies, H2 2017 (Contd..9), H2 2017 65
Number of Products under Development by Companies, H2 2017 (Contd..10), H2 2017 66
Number of Products under Development by Companies, H2 2017 (Contd..11), H2 2017 67
Number of Products under Development by Companies, H2 2017 (Contd..12), H2 2017 68
Number of Products under Development by Companies, H2 2017 (Contd..13), H2 2017 69
Number of Products under Development by Companies, H2 2017 (Contd..14), H2 2017 70
Number of Products under Development by Universities/Institutes, H2 2017 71
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 73
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 74
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017 75
Products under Development by Companies, H2 2017 76
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 77
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 78
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 79
Products under Development by Companies, H2 2017 (Contd..4), H2 2017 80
Products under Development by Companies, H2 2017 (Contd..5), H2 2017 81
Products under Development by Companies, H2 2017 (Contd..6), H2 2017 82
Products under Development by Companies, H2 2017 (Contd..7), H2 2017 83
Products under Development by Companies, H2 2017 (Contd..8), H2 2017 84
Products under Development by Companies, H2 2017 (Contd..9), H2 2017 85
Products under Development by Companies, H2 2017 (Contd..10), H2 2017 86
Products under Development by Companies, H2 2017 (Contd..11), H2 2017 87
Products under Development by Companies, H2 2017 (Contd..12), H2 2017 88
Products under Development by Companies, H2 2017 (Contd..13), H2 2017 89
Products under Development by Companies, H2 2017 (Contd..14), H2 2017 90
Products under Development by Companies, H2 2017 (Contd..15), H2 2017 91
Products under Development by Companies, H2 2017 (Contd..16), H2 2017 92
Products under Development by Companies, H2 2017 (Contd..17), H2 2017 93
Products under Development by Companies, H2 2017 (Contd..18), H2 2017 94
Products under Development by Companies, H2 2017 (Contd..19), H2 2017 95
Products under Development by Companies, H2 2017 (Contd..20), H2 2017 96
Products under Development by Universities/Institutes, H2 2017 97
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 98
Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 100
Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017 101
Number of Products by Stage and Target, H2 2017 103
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 104
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 105
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 106
Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017 107
Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017 108
Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017 109
Number of Products by Stage and Target, H2 2017 (Contd..7), H2 2017 110
Number of Products by Stage and Target, H2 2017 (Contd..8), H2 2017 111
Number of Products by Stage and Target, H2 2017 (Contd..9), H2 2017 112
Number of Products by Stage and Mechanism of Action, H2 2017 114
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 115
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 116
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 117
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017 118
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017 119
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..6), H2 2017 120
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..7), H2 2017 121
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..8), H2 2017 122
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..9), H2 2017 123
Number of Products by Stage and Route of Administration, H2 2017 125
Number of Products by Stage and Molecule Type, H2 2017 127
Number of Products by Stage and Molecule Type, H2 2017 (Contd..1), H2 2017 128
Glioblastoma Multiforme (GBM) - Pipeline by AbbVie Inc, H2 2017 129
Glioblastoma Multiforme (GBM) - Pipeline by Accurexa Inc, H2 2017 130
Glioblastoma Multiforme (GBM) - Pipeline by Actuate Therapeutics Inc, H2 2017 130
Glioblastoma Multiforme (GBM) - Pipeline by Aduro BioTech Inc, H2 2017 130
Glioblastoma Multiforme (GBM) - Pipeline by Advantagene Inc, H2 2017 131
Glioblastoma Multiforme (GBM) - Pipeline by Advenchen Laboratories LLC, H2 2017 131
Glioblastoma Multiforme (GBM) - Pipeline by Affimed GmbH, H2 2017 132
Glioblastoma Multiforme (GBM) - Pipeline by Agenus Inc, H2 2017 132
Glioblastoma Multiforme (GBM) - Pipeline by Ambrx Inc, H2 2017 133
Glioblastoma Multiforme (GBM) - Pipeline by Amgen Inc, H2 2017 133
Glioblastoma Multiforme (GBM) - Pipeline by Ampio Pharmaceuticals Inc, H2 2017 134
Glioblastoma Multiforme (GBM) - Pipeline by AngioChem Inc, H2 2017 134
Glioblastoma Multiforme (GBM) - Pipeline by Apac Biotech Pvt Ltd, H2 2017 134
Glioblastoma Multiforme (GBM) - Pipeline by apceth Biopharma GmbH, H2 2017 135
Glioblastoma Multiforme (GBM) - Pipeline by APIM Therapeutics AS, H2 2017 135
Glioblastoma Multiforme (GBM) - Pipeline by Apogenix AG, H2 2017 135
Glioblastoma Multiforme (GBM) - Pipeline by Ariad Pharmaceuticals Inc, H2 2017 136
Glioblastoma Multiforme (GBM) - Pipeline by Arog Pharmaceuticals Inc, H2 2017 136
Glioblastoma Multiforme (GBM) - Pipeline by Astellas Pharma Inc, H2 2017 137
Glioblastoma Multiforme (GBM) - Pipeline by AstraZeneca Plc, H2 2017 137
Glioblastoma Multiforme (GBM) - Pipeline by Athenex Inc, H2 2017 138
Glioblastoma Multiforme (GBM) - Pipeline by Basilea Pharmaceutica Ltd, H2 2017 138
Glioblastoma Multiforme (GBM) - Pipeline by Batu Biologics Inc, H2 2017 138
Glioblastoma Multiforme (GBM) - Pipeline by Bayer AG, H2 2017 139
Glioblastoma Multiforme (GBM) - Pipeline by Beactica AB, H2 2017 139
Glioblastoma Multiforme (GBM) - Pipeline by BeiGene Ltd, H2 2017 140
Glioblastoma Multiforme (GBM) - Pipeline by Berg LLC, H2 2017 140
Glioblastoma Multiforme (GBM) - Pipeline by Bexion Pharmaceuticals LLC, H2 2017 141
Glioblastoma Multiforme (GBM) - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2017 141
Glioblastoma Multiforme (GBM) - Pipeline by Bio-Path Holdings Inc, H2 2017 142
Glioblastoma Multiforme (GBM) - Pipeline by Bioasis Technologies Inc, H2 2017 142
Glioblastoma Multiforme (GBM) - Pipeline by BioCancell Ltd, H2 2017 142
Glioblastoma Multiforme (GBM) - Pipeline by Biovista Inc, H2 2017 143
Glioblastoma Multiforme (GBM) - Pipeline by Boehringer Ingelheim GmbH, H2 2017 143
Glioblastoma Multiforme (GBM) - Pipeline by Boston Biomedical Inc, H2 2017 144
Glioblastoma Multiforme (GBM) - Pipeline by Bristol-Myers Squibb Co, H2 2017 144
Glioblastoma Multiforme (GBM) - Pipeline by Cantex Pharmaceuticals Inc, H2 2017 145
Glioblastoma Multiforme (GBM) - Pipeline by Cavion LLC, H2 2017 145
Glioblastoma Multiforme (GBM) - Pipeline by Celgene Corp, H2 2017 146
Glioblastoma Multiforme (GBM) - Pipeline by Celldex Therapeutics Inc, H2 2017 146
Glioblastoma Multiforme (GBM) - Pipeline by Cellmid Ltd, H2 2017 147
Glioblastoma Multiforme (GBM) - Pipeline by Celsion Corp, H2 2017 147
Glioblastoma Multiforme (GBM) - Pipeline by ChemoCentryx Inc, H2 2017 148
Glioblastoma Multiforme (GBM) - Pipeline by Coherus BioSciences Inc, H2 2017 148
Glioblastoma Multiforme (GBM) - Pipeline by Cortice Biosciences Inc, H2 2017 149
Glioblastoma Multiforme (GBM) - Pipeline by Critical Outcome Technologies Inc, H2 2017 149
Glioblastoma Multiforme (GBM) - Pipeline by Curtana Pharmaceuticals Inc, H2 2017 149
Glioblastoma Multiforme (GBM) - Pipeline by Cynata Therapeutics Ltd, H2 2017 150
Glioblastoma Multiforme (GBM) - Pipeline by CytoVac AS, H2 2017 150
Glioblastoma Multiforme (GBM) - Pipeline by Daiichi Sankyo Co Ltd, H2 2017 151
Glioblastoma Multiforme (GBM) - Pipeline by Deciphera Pharmaceuticals LLC, H2 2017 151
Glioblastoma Multiforme (GBM) - Pipeline by DEKK-TEC Inc, H2 2017 151
Glioblastoma Multiforme (GBM) - Pipeline by DelMar Pharmaceuticals Inc, H2 2017 152
Glioblastoma Multiforme (GBM) - Pipeline by Diffusion Pharmaceuticals Inc, H2 2017 152
Glioblastoma Multiforme (GBM) - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2017 153
Glioblastoma Multiforme (GBM) - Pipeline by Ecrins Therapeutics SAS, H2 2017 153
Glioblastoma Multiforme (GBM) - Pipeline by Eisai Co Ltd, H2 2017 154
Glioblastoma Multiforme (GBM) - Pipeline by Eli Lilly and Co, H2 2017 154
Glioblastoma Multiforme (GBM) - Pipeline by EnGeneIC Ltd, H2 2017 155
Glioblastoma Multiforme (GBM) - Pipeline by Enterome Bioscience SA, H2 2017 155
Glioblastoma Multiforme (GBM) - Pipeline by EntreChem SL, H2 2017 155
Glioblastoma Multiforme (GBM) - Pipeline by ERC Belgium SA, H2 2017 156
Glioblastoma Multiforme (GBM) - Pipeline by Erytech Pharma SA, H2 2017 156
Glioblastoma Multiforme (GBM) - Pipeline by Evotec AG, H2 2017 157
Glioblastoma Multiforme (GBM) - Pipeline by F-star Biotechnology Ltd, H2 2017 157
Glioblastoma Multiforme (GBM) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 158
Glioblastoma Multiforme (GBM) - Pipeline by FirstString Research Inc, H2 2017 158
Glioblastoma Multiforme (GBM) - Pipeline by Fujifilm Holdings Corporation, H2 2017 159
Glioblastoma Multiforme (GBM) - Pipeline by Gene Techno Science Co Ltd, H2 2017 159
Glioblastoma Multiforme (GBM) - Pipeline by Genentech Inc, H2 2017 160
Glioblastoma Multiforme (GBM) - Pipeline by Genisphere LLC, H2 2017 160
Glioblastoma Multiforme (GBM) - Pipeline by Genor BioPharma Co Ltd, H2 2017 160
Glioblastoma Multiforme (GBM) - Pipeline by GlaxoSmithKline Plc, H2 2017 161
Glioblastoma Multiforme (GBM) - Pipeline by GlioPharma ApS, H2 2017 161
Glioblastoma Multiforme (GBM) - Pipeline by GtreeBNT Co Ltd, H2 2017 162
Glioblastoma Multiforme (GBM) - Pipeline by GW Pharmaceuticals Plc, H2 2017 162
Glioblastoma Multiforme (GBM) - Pipeline by Hamlet Pharma AB, H2 2017 162
Glioblastoma Multiforme (GBM) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017 163
Glioblastoma Multiforme (GBM) - Pipeline by Humanigen Inc, H2 2017 163
Glioblastoma Multiforme (GBM) - Pipeline by Hutchison MediPharma Ltd, H2 2017 164
Glioblastoma Multiforme (GBM) - Pipeline by Immatics Biotechnologies GmbH, H2 2017 164
Glioblastoma Multiforme (GBM) - Pipeline by Immune Pharmaceuticals Inc, H2 2017 165
Glioblastoma Multiforme (GBM) - Pipeline by ImmunoCellular Therapeutics Ltd, H2 2017 165
Glioblastoma Multiforme (GBM) - Pipeline by Immunomedics Inc, H2 2017 166
Glioblastoma Multiforme (GBM) - Pipeline by Immunomet Therapeutics Inc, H2 2017 166
Glioblastoma Multiforme (GBM) - Pipeline by Immunomic Therapeutics Inc, H2 2017 166
Glioblastoma Multiforme (GBM) - Pipeline by Incyte Corp, H2 2017 167
Glioblastoma Multiforme (GBM) - Pipeline by Infinity Pharmaceuticals Inc, H2 2017 167
Glioblastoma Multiforme (GBM) - Pipeline by Innovation Pharmaceuticals Inc, H2 2017 168
Glioblastoma Multiforme (GBM) - Pipeline by Inovio Pharmaceuticals Inc, H2 2017 168
Glioblastoma Multiforme (GBM) - Pipeline by Inspyr Therapeutics Inc, H2 2017 169
Glioblastoma Multiforme (GBM) - Pipeline by Insys Therapeutics Inc, H2 2017 169
Glioblastoma Multiforme (GBM) - Pipeline by Iovance Biotherapeutics Inc, H2 2017 170
Glioblastoma Multiforme (GBM) - Pipeline by Ipsen SA, H2 2017 170
Glioblastoma Multiforme (GBM) - Pipeline by Janpix Inc, H2 2017 171
Glioblastoma Multiforme (GBM) - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2017 171
Glioblastoma Multiforme (GBM) - Pipeline by Johnson & Johnson, H2 2017 172
Glioblastoma Multiforme (GBM) - Pipeline by Juno Therapeutics Inc, H2 2017 172
Glioblastoma Multiforme (GBM) - Pipeline by Kadmon Corp LLC, H2 2017 172
Glioblastoma Multiforme (GBM) - Pipeline by Karyopharm Therapeutics Inc, H2 2017 173
Glioblastoma Multiforme (GBM) - Pipeline by Kazia Therapeutics Ltd, H2 2017 173
Glioblastoma Multiforme (GBM) - Pipeline by Kite Pharma Inc, H2 2017 174
Glioblastoma Multiforme (GBM) - Pipeline by Komipharm International Co Ltd, H2 2017 174
Glioblastoma Multiforme (GBM) - Pipeline by Kringle Pharma Inc, H2 2017 175
Glioblastoma Multiforme (GBM) - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017 175
Glioblastoma Multiforme (GBM) - Pipeline by Les Laboratoires Servier SAS, H2 2017 176
Glioblastoma Multiforme (GBM) - Pipeline by Lixte Biotechnology Holdings Inc, H2 2017 176
Glioblastoma Multiforme (GBM) - Pipeline by Loxo Oncology Inc, H2 2017 176
Glioblastoma Multiforme (GBM) - Pipeline by Mabion SA, H2 2017 177
Glioblastoma Multiforme (GBM) - Pipeline by MacroGenics Inc, H2 2017 177
Glioblastoma Multiforme (GBM) - Pipeline by Medesis Pharma SA, H2 2017 178
Glioblastoma Multiforme (GBM) - Pipeline by Medicenna Therapeutics Corp, H2 2017 178
Glioblastoma Multiforme (GBM) - Pipeline by MedImmune LLC, H2 2017 179
Glioblastoma Multiforme (GBM) - Pipeline by Merck & Co Inc, H2 2017 179
Glioblastoma Multiforme (GBM) - Pipeline by Merck KGaA, H2 2017 180
Glioblastoma Multiforme (GBM) - Pipeline by Midatech Pharma Plc, H2 2017 180
Glioblastoma Multiforme (GBM) - Pipeline by Millennium Pharmaceuticals Inc, H2 2017 181
Glioblastoma Multiforme (GBM) - Pipeline by MimiVax LLC, H2 2017 181
Glioblastoma Multiforme (GBM) - Pipeline by Molecular Templates Inc, H2 2017 181
Glioblastoma Multiforme (GBM) - Pipeline by Moleculin Biotech Inc, H2 2017 182
Glioblastoma Multiforme (GBM) - Pipeline by Mycenax Biotech Inc, H2 2017 182
Glioblastoma Multiforme (GBM) - Pipeline by NanoCarrier Co Ltd, H2 2017 183
Glioblastoma Multiforme (GBM) - Pipeline by Nanomerics Ltd, H2 2017 183
Glioblastoma Multiforme (GBM) - Pipeline by Nektar Therapeutics, H2 2017 184
Glioblastoma Multiforme (GBM) - Pipeline by Neonc Technologies Inc, H2 2017 184
Glioblastoma Multiforme (GBM) - Pipeline by NewLink Genetics Corp, H2 2017 185
Glioblastoma Multiforme (GBM) - Pipeline by Northwest Biotherapeutics Inc, H2 2017 185
Glioblastoma Multiforme (GBM) - Pipeline by Novartis AG, H2 2017 186
Glioblastoma Multiforme (GBM) - Pipeline by Noxopharm Ltd, H2 2017 186
Glioblastoma Multiforme (GBM) - Pipeline by Noxxon Pharma AG, H2 2017 186
Glioblastoma Multiforme (GBM) - Pipeline by Nuo Therapeutics Inc, H2 2017 187
Glioblastoma Multiforme (GBM) - Pipeline by NuvOx Pharma LLC, H2 2017 187
Glioblastoma Multiforme (GBM) - Pipeline by Omniox Inc, H2 2017 188
Glioblastoma Multiforme (GBM) - Pipeline by Oncobiologics Inc, H2 2017 188
Glioblastoma Multiforme (GBM) - Pipeline by Oncodesign SA, H2 2017 189
Glioblastoma Multiforme (GBM) - Pipeline by Onconova Therapeutics Inc, H2 2017 189
Glioblastoma Multiforme (GBM) - Pipeline by OncoResponse Inc, H2 2017 189
Glioblastoma Multiforme (GBM) - Pipeline by Oncternal Therapeutics Inc, H2 2017 190
Glioblastoma Multiforme (GBM) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 190
Glioblastoma Multiforme (GBM) - Pipeline by Orphit SAS, H2 2017 191
Glioblastoma Multiforme (GBM) - Pipeline by Oryx GmbH & Co KG, H2 2017 191
Glioblastoma Multiforme (GBM) - Pipeline by Ovensa Inc, H2 2017 191
Glioblastoma Multiforme (GBM) - Pipeline by Peloton Therapeutics Inc, H2 2017 192
Glioblastoma Multiforme (GBM) - Pipeline by Peptomyc SL, H2 2017 192
Glioblastoma Multiforme (GBM) - Pipeline by Peregrine Pharmaceuticals Inc, H2 2017 193
Glioblastoma Multiforme (GBM) - Pipeline by Pfizer Inc, H2 2017 193
Glioblastoma Multiforme (GBM) - Pipeline by Pharma Mar SA, H2 2017 194
Glioblastoma Multiforme (GBM) - Pipeline by PharmAbcine Inc, H2 2017 194
Glioblastoma Multiforme (GBM) - Pipeline by PharmaCyte Biotech Inc, H2 2017 195
Glioblastoma Multiforme (GBM) - Pipeline by Pharmicell Co Ltd, H2 2017 195
Glioblastoma Multiforme (GBM) - Pipeline by Phoenix Biotechnology Inc, H2 2017 196
Glioblastoma Multiforme (GBM) - Pipeline by PIQUR Therapeutics AG, H2 2017 196
Glioblastoma Multiforme (GBM) - Pipeline by Plex Pharmaceuticals Inc, H2 2017 196
Glioblastoma Multiforme (GBM) - Pipeline by Plexxikon Inc, H2 2017 197
Glioblastoma Multiforme (GBM) - Pipeline by Prana Biotechnology Ltd, H2 2017 197
Glioblastoma Multiforme (GBM) - Pipeline by PTC Therapeutics Inc, H2 2017 198
Glioblastoma Multiforme (GBM) - Pipeline by Puma Biotechnology Inc, H2 2017 198
Glioblastoma Multiforme (GBM) - Pipeline by Regulus Therapeutics Inc, H2 2017 199
Glioblastoma Multiforme (GBM) - Pipeline by ReNeuron Group Plc, H2 2017 199
Glioblastoma Multiforme (GBM) - Pipeline by Rgenix Inc, H2 2017 199
Glioblastoma Multiforme (GBM) - Pipeline by Richter Gedeon Nyrt, H2 2017 200
Glioblastoma Multiforme (GBM) - Pipeline by Sanofi, H2 2017 200
Glioblastoma Multiforme (GBM) - Pipeline by Sapience Therapeutics Inc, H2 2017 201
Glioblastoma Multiforme (GBM) - Pipeline by Scancell Holdings Plc, H2 2017 201
Glioblastoma Multiforme (GBM) - Pipeline by Sellas Life Sciences Group Ltd, H2 2017 202
Glioblastoma Multiforme (GBM) - Pipeline by Sigma-Tau SpA, H2 2017 202
Glioblastoma Multiforme (GBM) - Pipeline by SignPath Pharma Inc, H2 2017 202
Glioblastoma Multiforme (GBM) - Pipeline by Silenseed Ltd, H2 2017 203
Glioblastoma Multiforme (GBM) - Pipeline by SOM Biotech SL, H2 2017 203
Glioblastoma Multiforme (GBM) - Pipeline by Sorrento Therapeutics Inc, H2 2017 204
Glioblastoma Multiforme (GBM) - Pipeline by StemGen SpA, H2 2017 204
Glioblastoma Multiforme (GBM) - Pipeline by Stemline Therapeutics Inc, H2 2017 205
Glioblastoma Multiforme (GBM) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017 205
Glioblastoma Multiforme (GBM) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 206
Glioblastoma Multiforme (GBM) - Pipeline by Sunesis Pharmaceuticals Inc, H2 2017 206
Glioblastoma Multiforme (GBM) - Pipeline by Susavion Biosciences Inc, H2 2017 207
Glioblastoma Multiforme (GBM) - Pipeline by Symphogen A/S, H2 2017 207
Glioblastoma Multiforme (GBM) - Pipeline by Synactix Pharmaceuticals Inc, H2 2017 207
Glioblastoma Multiforme (GBM) - Pipeline by Systimmune Inc, H2 2017 208
Glioblastoma Multiforme (GBM) - Pipeline by Terpenoid Therapeutics Inc, H2 2017 208
Glioblastoma Multiforme (GBM) - Pipeline by Theralase Technologies Inc, H2 2017 209
Glioblastoma Multiforme (GBM) - Pipeline by Therapeia GmbH & Co KG, H2 2017 209
Glioblastoma Multiforme (GBM) - Pipeline by Tocagen Inc, H2 2017 209
Glioblastoma Multiforme (GBM) - Pipeline by TRACON Pharmaceuticals Inc, H2 2017 210
Glioblastoma Multiforme (GBM) - Pipeline by Transgene SA, H2 2017 210
Glioblastoma Multiforme (GBM) - Pipeline by Trillium Therapeutics Inc, H2 2017 211
Glioblastoma Multiforme (GBM) - Pipeline by TVAX Biomedical Inc, H2 2017 211
Glioblastoma Multiforme (GBM) - Pipeline by Tyme Technologies Inc, H2 2017 211
Glioblastoma Multiforme (GBM) - Pipeline by Upsher-Smith Laboratories Inc, H2 2017 212
Glioblastoma Multiforme (GBM) - Pipeline by Vascular Biogenics Ltd, H2 2017 212
Glioblastoma Multiforme (GBM) - Pipeline by Vault Pharma Inc, H2 2017 213
Glioblastoma Multiforme (GBM) - Pipeline by Vaximm AG, H2 2017 213
Glioblastoma Multiforme (GBM) - Pipeline by VBI Vaccines Inc, H2 2017 213
Glioblastoma Multiforme (GBM) - Pipeline by VCN Biosciences SL, H2 2017 214
Glioblastoma Multiforme (GBM) - Pipeline by ViraTherapeutics GmbH, H2 2017 214
Glioblastoma Multiforme (GBM) - Pipeline by Vyriad Inc, H2 2017 215
Glioblastoma Multiforme (GBM) - Pipeline by X4 Pharmaceuticals Inc, H2 2017 215
Glioblastoma Multiforme (GBM) - Pipeline by Xintela AB, H2 2017 215
Glioblastoma Multiforme (GBM) - Pipeline by Yooyoung Pharm Co Ltd, H2 2017 216
Glioblastoma Multiforme (GBM) - Pipeline by ZIOPHARM Oncology Inc, H2 2017 216
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 1546
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd..1), H2 2017 1547
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd..2), H2 2017 1548
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd..3), H2 2017 1549
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd..4), H2 2017 1550
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd..5), H2 2017 1551
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd..6), H2 2017 1552
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd..7), H2 2017 1553
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd..8), H2 2017 1554
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd..9), H2 2017 1555
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd..10), H2 2017 1556
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd..11), H2 2017 1557
Glioblastoma Multiforme (GBM) - Discontinued Products, H2 2017 1558
Glioblastoma Multiforme (GBM) - Discontinued Products, H2 2017 (Contd..1), H2 2017 1559

List of Figures
Number of Products under Development for Glioblastoma Multiforme (GBM), H2 2017 54
Number of Products under Development by Companies, H2 2017 55
Number of Products under Development by Universities/Institutes, H2 2017 71
Number of Products by Top 10 Targets, H2 2017 102
Number of Products by Stage and Top 10 Targets, H2 2017 102
Number of Products by Top 10 Mechanism of Actions, H2 2017 113
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 113
Number of Products by Top 10 Routes of Administration, H2 2017 124
Number of Products by Stage and Top 10 Routes of Administration, H2 2017 124
Number of Products by Top 10 Molecule Types, H2 2017 126
Number of Products by Stage and Top 10 Molecule Types, H2 2017 126

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *